Research programme: anti-tropomyosin therapeutics - Kazia Therapeutics

Drug Profile

Research programme: anti-tropomyosin therapeutics - Kazia Therapeutics

Alternative Names: Anisina; Anti-tropomyosins - Kazia Therapeutics; ATM drugs - Kazia Therapeutics; ATM-3507; Tm5NM1 protein inhibitors - Kazia Therapeutics; Tpm3.1 protein inhibitors - Kazia Therapeutics; TR 100

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genscreen; University of New South Wales
  • Developer Kazia Therapeutics; Nationwide Children's Hospital
  • Class Small molecules
  • Mechanism of Action Tropomyosin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Malignant melanoma; Prostate cancer
  • No development reported Neuroblastoma; Ovarian cancer

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Neuroblastoma in Australia (IV)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Neuroblastoma in USA (IV)
  • 28 Jul 2018 No recent reports of development identified for research development in Ovarian-cancer in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top